scholarly journals Role of socioeconomic disparities in incidence and mortality of chronic kidney disease

2017 ◽  
Vol 4 (12) ◽  
pp. 1847
Author(s):  
Mahdi Mohammadian ◽  
Hamid Salehiniya ◽  
Fatemeh Allah Bakeshei ◽  
Abdollah Mohammadian-Hafshejani
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Public Health Problem ◽  
Premature Death ◽  
Strong Relationship ◽  
Incidence And Mortality ◽  
Key Factor ◽  
Incidence Of Ckd ◽  
Socio Economic Factors

Chronic kidney disease (CKD) is a public health problem known as one of the most important factors for premature death (Coresh et al., 2007; Martins et al., 2012). The disparity in the distribution of CKD is due to the socio-economic factors, gender, ethnicity and race at the global level (Norris and Nissenson, 2008; Norris and Agodoa, 2005). Roles of socio-economic conditions have been recently taken into account as a key factor in the pathway of CKD creation and expansion (Bruce et al., 2009; Nicholas et al., 2015). Several studies worldwide investigated a strong relationship between socioeconomic status and incidence of CKD complications (Crews et al., 2012; Jurkovitz et al., 2012; Saab et al., 2012).

scholarly journals The role of hemostatic disorders in the progression of chronic kidney disease

2019 ◽  
pp. 49-55
Author(s):  
I. Dudar ◽  
I. Mykhaloiko
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Kidney Diseases ◽  
Public Health Problem ◽  
Premature Death ◽  
Coagulation System ◽  
Global Public Health ◽  
Stage Renal Disease ◽  
End Stage ◽  
Hemostatic Disorders

Chronic kidney disease (CKD) has become a global public health problem because of its high prevalence and the accompanying increase in the risk of end-stage renal disease, cardiovascular disease, and premature death. At present there is a number of experimental and clinical data that show that one of the important mechanisms of the pathogenesis of CKD is a violation of the blood coagulation system (hemostasis) both locally in the kidneys and with the capture of the microcirculatory channel of other organs, therefore an important task for specialists in the  nephrology, as well as doctors of other specialties is  understanding  the functioning of the system of hemostasis in normal and in various kidney diseases and the correction of this pathology with drugs. There are several types of haemostasis disorders that may occur in CKD: disseminated intravascular coagulation syndrome (DIC), arterial and venous thrombosis and bleeding. In this review, we tried to determine the place of the DIC in the development and progress of the CKD and to assess the prospects for further research.

scholarly journals The unanswered Questions in Hyperuricemia: is it a cause of chronic kidney disease, a compensation mechanism, a coincidence, a consequence of disease or concurrent phenomenon?

2018 ◽  
pp. 48-61
Author(s):  
M. Kolesnyk
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Public Health Problem ◽  
Premature Death ◽  
Current Evidence ◽  
Global Public Health ◽  
High Prevalence ◽  
Therapy Effectiveness ◽  
Stage Renal Disease ◽  
End Stage

Chronic kidney disease (CKD) has become a global public health problem because of its high prevalence and the accompanying increase in the risk of end-stage renal disease, cardiovascular disease, and premature death. The role of uric acid (UA) in the pathogenesis and progression of CKD remains controversial. Although many evidence-based studies have suggested that UA itself may harm patients with CKD by increasing inflammation and CKD progression, the issue is still a matter of discussions. In this review we try to clarify what is hyperuricemia – cause of CKD, compensation, coincidence, consequence of CKD or it is only an epiphenomenon, and to evaluate current evidence of different types of targeted hypouricemic therapy effectiveness. So, to treat or not to treat?

scholarly journals Urobiome: In Sickness and in Health

2019 ◽  
Vol 7 (11) ◽  
pp. 548 ◽  
Author(s):  
Bartosz Wojciuk ◽  
Agata Salabura ◽  
Bartłomiej Grygorcewicz ◽  
Karolina Kędzierska ◽  
Kazimierz Ciechanowski ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Transplantation ◽  
Kidney Disease ◽  
Human Microbiome ◽  
Human Condition ◽  
Challenges And Opportunities ◽  
Key Factor ◽  
Urological Disorders ◽  
Generation Sequencing

The human microbiome has been proven to contribute to the human condition, both in health and in disease. The metagenomic approach based on next-generation sequencing has challenged the dogma of urine sterility. The human urobiome consists of bacteria and eukaryotic viruses as well as bacteriophages, which potentially represent the key factor. There have been several significant findings with respect to the urobiome in the context of urological disorders. Still, the research on the urobiome in chronic kidney disease and kidney transplantation remains underrepresented, as does research on the role of the virome in the urinary microbiota. In this review, we present recent findings on the urobiome with a particular emphasis on chronic kidney disease and post-kidney transplantation status. Challenges and opportunities arising from the research on the human urobiome will also be discussed.

scholarly journals Chronic Kidney Disease, Obesity, and Hypertension: The Role of Leptin and Adiponectin

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
M. Tesauro ◽  
A. Mascali ◽  
O. Franzese ◽  
S. Cipriani ◽  
C. Cardillo ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Kidney Disease ◽  
Kidney Injury ◽  
Public Health Problem ◽  
Major Public Health Problem ◽  
Renal Progression ◽  
Obesity Hypertension ◽  
Progression Factor

Chronic kidney disease is a major public health problem and characterized by a progressive loss in renal function over a period of months or years as defined by structural or functional abnormalities of the kidney. Several elements contribute to determine a progression of the kidney injury, inducing a worsening of renal damage and accelerating the decline of renal function: obesity and hypertension are two known factors of kidney progression. Remarkable improvements have been recently achieved in the study of the endocrine features of the adipose tissue and have been able to produce hormone-like peptides named adipokines or adipocytokines. Among these adipocytokines, which represent a link between obesity, hypertension, and chronic nephropathy, leptins and adiponectin appear to play an important role. Leptin not only is a prohypertension element (renal progression factor) through the activation sympathetic nervous, but also is able to induce prosclerotic effects directly on the kidney. In contrast, a decline of adiponectin levels has been shown to be related to a picture of hypertension: an endothelial dysfunction has been described as the main pathogenic mechanism responsible for this phenomenon.

CLINICAL AND THERAPEUTIC VALUE OF ADIPOKINES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

2020 ◽  
pp. 5-9
Author(s):  
Ya. M Fylenko
Keyword(s):  
Cardiovascular Disease ◽  
Chronic Kidney Disease ◽  
Adipose Tissue ◽  
Kidney Disease ◽  
Therapeutic Potential ◽  
Interdisciplinary Approach ◽  
Blood Lipid ◽  
The Body ◽  
Incidence And Mortality

This review is devoted to the analysis of the role of adipokines in formation of pathological changes in renal function and structure. The patients with chronic kidney disease have a high risk of cardiovascular disease. Currently, the role of systemic hormonal and metabolic factors in the pathogenesis of the kidneys is growing. A promising area of pathogenetic prevention and treatment of kidney disease is an interdisciplinary approach, whereat the adipokine imbalance is of particular interest. Adipose tissue and its messengers, adipokines, are known to be highly associated with kidney disease. Adipocytes are metabolically active cells, producing the signaling lipids, metabolites and protein factors, i.e. adipokines. The interaction of adipose tissue with the kidney is called the adipose kidney axis, being important for the normal functioning of the body, as well as its response to an injury. It has a strong therapeutic potential in respect of the growing rates of chronic kidney disease. Adipocyte hypertrophy is often accompanied by the development of tissue fibrosis, hypoxia, and secretion of pro−inflammatory cytokines (such as tumor necrosis factor or interleukin, which triggers the cell inflammation). Dysfunction of adipose tissue contributes to the development of cardiovascular disease at the local and systemic levels. Thus, for the early diagnosis of chronic kidney disease into the diagnostic program, in addition to the generally accepted indices, the determination of adipokines: for example, serum leptin, adiponectin, omentin, visfatin, microalbuminuria, blood lipid spectrum, intrarenal and functional status of the kidneys with the assessment of functional renal reserve is recommended to be included. Early detection of the disease, new approaches to its diagnosis and treatment can help in reducing the risk of a high incidence and mortality from renal disease. Key words: chronic kidney disease, nephropathy, adipokines, leptin, resistin, adiponectin, visfatin, omentin.

PREVALENCE OF ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS

2021 ◽  
Vol 5 (2) ◽  
Author(s):  
Asma Ismail Alismail
Keyword(s):  
Chronic Kidney Disease ◽  
Standard Deviation ◽  
Kidney Disease ◽  
Significant Risk ◽  
Public Health Problem ◽  
Premature Death ◽  
Significant Risk Factor ◽  
The Mean ◽  
End Stage ◽  
Prevalence Of Anemia

Background: Chronic kidney disease (CKD), defined as renal damage with persistent and usually progressive deterioration of ultrafiltration, is a worldwide public health problem. Is considered as a significant risk factor for end-stage renal disease, anemia, cardiovascular disease, and premature death. The aging of the population and the generally increasing rates of obesity, hypertension, and diabetes worldwide suggest that the incidence and prevalence of CKD will rise over the next decades. Materials and Method: The data will consider all patients visiting outpatient’s department at the primary health center attached to King Faisal University in Al-Ahsa  between 1st January 2010 and 31st December 2011. From the patients` files, we was record the age, gender, GFR, stages of CKD and state of anemia. Results: In this study, 49.3% of participants were male, and 50.7% was female—only 2.6% of participants on hemodialysis. The prevalence of anemia among the participants in our study was 55.5%. According to the results of the participants in this research, the mean age was 57.82, with a standard deviation of 17.067. The mean Hemoglobin of the participants was 11.775, with a standard deviation of 2.5334. The mean results of the participants by using CKD-EPI formula, to calculate GFR was 74.496 with a standard a deviation of 36.6787, which was the lowest mean of GFR. In Quadratic EGFR formula that was used to calculate GFR, the mean was 84.47 with a standard deviation of 35.677, which was the highest mean of GFR. DMRD formula was also used in this research to calculate the GFR, with a mean of 78.84 with a standard deviation of 50.371. Conclusions: In our data analysis, 100% of patients in the end stage of CKD had anemia although we used three different formulas to calculate GFR; however, the result was the same regarding patients in the end-stage. A surprising fact was found looking to other stages of CKD, and it is a correlation with anemia, the analysis of the data in this study did not show an increasing number of anemic patients to the stage of CKD in a stepwise manner. Keyword: Anemia, CKD, Al-Ahsa

scholarly journals Critical Role for AMPK in Metabolic Disease-Induced Chronic Kidney Disease

2020 ◽  
Vol 21 (21) ◽  
pp. 7994 ◽  
Author(s):  
Florian Juszczak ◽  
Nathalie Caron ◽  
Anna V. Mathew ◽  
Anne-Emilie Declèves
Keyword(s):  
Metabolic Disease ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Mammalian Cells ◽  
Critical Role ◽  
Public Health Problem ◽  
Nutrient Sensing ◽  
Renal Diseases ◽  
Renal Cells

Chronic kidney disease (CKD) is prevalent in 9.1% of the global population and is a significant public health problem associated with increased morbidity and mortality. CKD is associated with highly prevalent physiological and metabolic disturbances such as hypertension, obesity, insulin resistance, cardiovascular disease, and aging, which are also risk factors for CKD pathogenesis and progression. Podocytes and proximal tubular cells of the kidney strongly express AMP-activated protein kinase (AMPK). AMPK plays essential roles in glucose and lipid metabolism, cell survival, growth, and inflammation. Thus, metabolic disease-induced renal diseases like obesity-related and diabetic chronic kidney disease demonstrate dysregulated AMPK in the kidney. Activating AMPK ameliorates the pathological and phenotypical features of both diseases. As a metabolic sensor, AMPK regulates active tubular transport and helps renal cells to survive low energy states. AMPK also exerts a key role in mitochondrial homeostasis and is known to regulate autophagy in mammalian cells. While the nutrient-sensing role of AMPK is critical in determining the fate of renal cells, the role of AMPK in kidney autophagy and mitochondrial quality control leading to pathology in metabolic disease-related CKD is not very clear and needs further investigation. This review highlights the crucial role of AMPK in renal cell dysfunction associated with metabolic diseases and aims to expand therapeutic strategies by understanding the molecular and cellular processes underlying CKD.

scholarly journals Role of Myeloperoxidase in Patients with Chronic Kidney Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Bojana Kisic ◽  
Dijana Miric ◽  
Ilija Dragojevic ◽  
Julijana Rasic ◽  
Ljiljana Popovic
Keyword(s):  
Oxidative Stress ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Public Health Problem ◽  
Cardiovascular Complications ◽  
The Body ◽  
Stage Renal Disease ◽  
End Stage

Chronic kidney disease (CKD) is a worldwide public health problem. Patients with CKD have a number of disorders in the organism, and the presence of oxidative stress and systemic inflammation in these patients is the subject of numerous studies. Chronic inflammation joined with oxidative stress contributes to the development of numerous complications: accelerated atherosclerosis process and cardiovascular disease, emergence of Type 2 diabetes mellitus, development of malnutrition, anaemia, hyperparathyroidism, and so forth, affecting the prognosis and quality of life of patients with CKD. In this review we presented the potential role of the myeloperoxidase enzyme in the production of reactive/chlorinating intermediates and their role in oxidative damage to biomolecules in the body of patients with chronic kidney disease and end-stage renal disease. In addition, we discussed the role of modified lipoprotein particles under the influence of prooxidant MPO intermediates in the development of endothelial changes and cardiovascular complications in renal failure.

scholarly journals The Prognosis of Patients with Chronic Kidney Disease and Diabetes Mellitus

2014 ◽  
Vol 21 (3) ◽  
pp. 203-212
Author(s):  
Mihaela Vladu ◽  
Diana Clenciu ◽  
Mihaela Bîcu ◽  
Maria Mofa
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Vascular Complications ◽  
Public Health Problem ◽  
Premature Death ◽  
Study Groups ◽  
Adverse Outcomes ◽  
Significant Difference ◽  
Recorded Data

AbstractBackground and Aims: Diabetes mellitus (DM) is a chronic disease which can evolve towards devastating micro and macro-vascular complications. Chronic kidney disease (CKD) is a worldwide public health problem, with adverse outcomes of kidney failure, cardiovascular disease (CVD) and premature death. The aim of our study was to evaluate the prognosis in patients with DM and CKD, depending on estimated glomerular filtration rate (eGFR) and albuminuria, according to the classification of Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (KDIGO) from 2013 Materials and Methods: The study was epidemiological, transversal, non interventional type, with 600 subjects unselected patients divided into three subgroups: 200 patients with T1DM, 200 patients with T2DM and 200 age matched subjects without DM. The recorded data have been analyzed using the Statistic Package for Social Sciences (SPSS), the 17.00 software (IBM Corporation, Armonk, NY, United States of America). Results:. We found a statistically significant difference among the three study groups (p < 0.0001) regarding the prognosis of CKD. Conclusions: DM represents an important risk factor for the appearance of CKD but also a negative prognosis factor for the patients with CKD.

Potential effect of pharmaceutical care to improve outcomes in patients with chronic kidney disease-mineral bone disorder in Sulaimani dialysis centers

2020 ◽  
pp. 82-94
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pharmaceutical Care ◽  
Biochemical Parameters ◽  
Positive Impact ◽  
Potential Effect ◽  
Care Group ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Objective: the present study was aimed to evaluate the role of pharmaceutical services in improving the outcome of mineral bone disorder in patients with advanced chronic kidney disease. Methodology: One hundred and twenty patients with chronic kidney disease-mineral bone disorder (CKD-MBD) screened for eligibility, seventy-six patients enrolled in the study and randomly allocated into two groups: pharmaceutical care and usual care, both groups interviewed by the pharmacist using specific questionnaire for assessing the quality of life (QoL). All the drug related problems (DRPs) including drug-drug interactions (DDIs) were recorded by the pharmacist. Blood samples were collected and utilized for analyzing the levels of vitamin D, phosphorous, calcium, albumin and parathyroid hormone at baseline and three months after. The pharmaceutical care group received all the educations about their medications and how to minimize DRPs; improve the QoL. Additionally, the pharmaceutical intervention included correcting the biochemical parameters. Results: Pharmaceutical care significantly improved patients QoL and minimized DRPs and DDIs. It was also effective in improving the biochemical parameters. Conclusion: Pharmaceutical care has a positive impact on improving the outcome of patients with CKD-MBD through attenuating DRPs, improving the biochemical parameters and the QoL.

Sign in / Sign up

Export Citation Format

Share Document